The Sarandria Score—Discussion of a New Scoring System in Clinical Medical Oncology
Nicola Sarandria
{"title":"The Sarandria Score—Discussion of a New Scoring System in Clinical Medical Oncology","authors":"Nicola Sarandria","doi":"10.4236/ijcm.2022.133010","DOIUrl":null,"url":null,"abstract":"This paper focuses on discussing a novel scoring for stage III rectal cancer patients and all the challenges in creating and developing a clinical score. Background: It is fundamental in my opinion to give space to new generations of scientists, medical doctors and researchers to study and, backed with evidence-based information, improve the current knowledge of clinical medical science. It is fundamental for result obtained by medical researchers to bring their findings to the scientific community. Every scientific finding is of vital importance. In this essay a new Clinical Scoring system, the Sarandria Score, developed by myself is discussed, together with the methods and path in order for a young medical researcher with an idea to bring it to the scientific community. Main topics: Colorectal Cancer (CRC) is a major public health problem, representing the third most commonly diagnosed cancer in males and the second in females. Various studies have reported relevant differences related to CRC primary location site (right-sided colon, left-sided colon, rectum) including response to adjuvant chemotherapy and prognosis. In stage III CRC patients, previous findings showed that higher density of tumor-associated neutrophils (TANs) was associated with better response to 5-FU-based chemotherapy. Novel findings were discovered by Dr Nicola Sarandria on the role of neutrophils in rectal cancer, which include different factors which point to an anti-tumoral role of neutrophils in rectal cancer when in presence of chemotherapeutic agents (5-fluorouracil). The clinical significance of TANs was assessed and whether it can be different depended on the location of the primary CRC (right-sided colon, left-sided colon, rectum). Conclusions: This essay officially discusses a new clinical prognostic and predictive scoring (Sarandria Score) involving intratumoral neutrophilic infiltration in rectal cancer and the possibility of a new inclusion criteria based on this infiltrate for Stage III rectal cancer patients treated with 5-FU therapy. This paper includes data published on my medical degree thesis and in a previous review (on Journal of Cancer Therapy) showing that higher leHow to cite this paper: Sarandria, N. (2022) The Sarandria Score—Discussion of a New Scoring System in Clinical Medical Oncolog. International Journal of Clinical Medicine, 13, 121-131. https://doi.org/10.4236/ijcm.2022.133010 Received: January 24, 2022 Accepted: March 13, 2022 Published: March 16, 2022 Copyright © 2022 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access RE TR AC TE D","PeriodicalId":58771,"journal":{"name":"临床医学国际期刊(英文)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"临床医学国际期刊(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4236/ijcm.2022.133010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This paper focuses on discussing a novel scoring for stage III rectal cancer patients and all the challenges in creating and developing a clinical score. Background: It is fundamental in my opinion to give space to new generations of scientists, medical doctors and researchers to study and, backed with evidence-based information, improve the current knowledge of clinical medical science. It is fundamental for result obtained by medical researchers to bring their findings to the scientific community. Every scientific finding is of vital importance. In this essay a new Clinical Scoring system, the Sarandria Score, developed by myself is discussed, together with the methods and path in order for a young medical researcher with an idea to bring it to the scientific community. Main topics: Colorectal Cancer (CRC) is a major public health problem, representing the third most commonly diagnosed cancer in males and the second in females. Various studies have reported relevant differences related to CRC primary location site (right-sided colon, left-sided colon, rectum) including response to adjuvant chemotherapy and prognosis. In stage III CRC patients, previous findings showed that higher density of tumor-associated neutrophils (TANs) was associated with better response to 5-FU-based chemotherapy. Novel findings were discovered by Dr Nicola Sarandria on the role of neutrophils in rectal cancer, which include different factors which point to an anti-tumoral role of neutrophils in rectal cancer when in presence of chemotherapeutic agents (5-fluorouracil). The clinical significance of TANs was assessed and whether it can be different depended on the location of the primary CRC (right-sided colon, left-sided colon, rectum). Conclusions: This essay officially discusses a new clinical prognostic and predictive scoring (Sarandria Score) involving intratumoral neutrophilic infiltration in rectal cancer and the possibility of a new inclusion criteria based on this infiltrate for Stage III rectal cancer patients treated with 5-FU therapy. This paper includes data published on my medical degree thesis and in a previous review (on Journal of Cancer Therapy) showing that higher leHow to cite this paper: Sarandria, N. (2022) The Sarandria Score—Discussion of a New Scoring System in Clinical Medical Oncolog. International Journal of Clinical Medicine, 13, 121-131. https://doi.org/10.4236/ijcm.2022.133010 Received: January 24, 2022 Accepted: March 13, 2022 Published: March 16, 2022 Copyright © 2022 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access RE TR AC TE D
Sarandria评分——临床肿瘤学新评分系统的探讨
本文重点讨论了一种用于III期直肠癌患者的新型评分方法,以及创建和发展临床评分方法所面临的所有挑战。背景:在我看来,为新一代科学家、医生和研究人员提供学习空间,并在循证信息的支持下,改善临床医学的现有知识,这是至关重要的。医学研究人员获得的成果将其发现带到科学界是至关重要的。每一项科学发现都至关重要。在这篇文章中,讨论了一个新的临床评分系统,Sarandria评分,我自己开发的,连同方法和路径,以便一个年轻的医学研究人员有一个想法,把它带到科学界。主要主题:结直肠癌(CRC)是一个重大的公共卫生问题,是男性中第三大最常诊断的癌症,在女性中排名第二。各种研究报道了CRC原发部位(右侧结肠、左侧结肠、直肠)的相关差异,包括对辅助化疗的反应和预后。在III期CRC患者中,先前的研究结果显示,肿瘤相关中性粒细胞(TANs)密度较高与基于5- fu的化疗反应较好相关。Nicola Sarandria博士发现了中性粒细胞在直肠癌中的作用的新发现,其中包括不同的因素,这些因素指出了当化疗药物(5-氟尿嘧啶)存在时,中性粒细胞在直肠癌中的抗肿瘤作用。评估TANs的临床意义,根据原发结直肠癌的位置(右侧结肠、左侧结肠、直肠),TANs是否会有所不同。结论:本文正式讨论了一种新的临床预后和预测评分(Sarandria评分),涉及直肠癌肿瘤内嗜中性粒细胞浸润,以及基于这种浸润的新纳入标准的可能性,该标准适用于接受5-FU治疗的III期直肠癌患者。这篇论文包括我的医学学位论文和之前的一篇综述(Journal of Cancer Therapy)中发表的数据,显示更高的水平。如何引用这篇论文:Sarandria, N. (2022) The Sarandria Score-Discussion of a New Scoring System in Clinical medical oncology。国际临床医学杂志,13,121-131。https://doi.org/10.4236/ijcm.2022.133010收稿日期:2022年1月24日收稿日期:2022年3月13日出版日期:2022年3月16日版权所有©2022由作者和Scientific Research Publishing Inc。本作品采用知识共享署名国际许可协议(CC BY 4.0)。http://creativecommons.org/licenses/by/4.0/开放存取RE TR AC D
本文章由计算机程序翻译,如有差异,请以英文原文为准。